Den mediane PFS var 42, 2 måneder i MabThera vedligeholdelsesarmen sammenlignet med 14, 3 måneder i observationsarmen.
Using a cox regression analysis, the risk of experiencing progressive disease or death was reduced by 61% with MabThera maintenance treatment when compared to observation (95% CI; 45 %-72%).